Lexeo Therapeutics (LXEO) Cash from Operations (2022 - 2026)

Lexeo Therapeutics has disclosed Cash from Operations across 5 years of filings, most recently posting 21144000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 21144000.0, up 2.63% year-over-year; the trailing twelve-month figure through Mar 2026 was 97989000.0 (down 11.35% YoY), and the FY2025 annual result was 98561000.0, down 21.45% from the prior year.
• Cash from Operations came in at 21144000.0 for Q1 2026 at Lexeo Therapeutics, down from 20079000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 13192000.0 in Q2 2023 to a low of 29547000.0 in Q3 2025.
• The 5-year median for Cash from Operations is 19226500.0 (2023), against an average of 19784142.86.
• Across the five-year window, Cash from Operations sank 102.6% in 2024 and increased 29.11% in 2025, its largest moves.
• Lexeo Therapeutics' Cash from Operations stood at 16626000.0 in 2022, then advanced by 15.91% to 13981000.0 in 2023, then slumped by 102.6% to 28326000.0 in 2024, then climbed by 29.11% to 20079000.0 in 2025, then dropped by 5.3% to 21144000.0 in 2026.
• The last three Cash from Operations figures came in at 21144000.0 (Q1 2026), 20079000.0 (Q4 2025), and 29547000.0 (Q3 2025), per Business Quant data.